{"id":949939,"date":"2026-04-08T16:04:24","date_gmt":"2026-04-08T20:04:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/"},"modified":"2026-04-08T16:04:24","modified_gmt":"2026-04-08T20:04:24","slug":"stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","title":{"rendered":"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference"},"content":{"rendered":"

<\/p>\n

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference<\/b><\/p>\n

BEDFORD, Mass.–(BUSINESS WIRE<\/a>)–Stoke Therapeutics, Inc.<\/a> (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:00 p.m. ET.<\/p>\n

\nA live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke\u2019s website at https:\/\/investor.stoketherapeutics.com\/<\/a>.<\/p>\n

About Stoke Therapeutics<\/b><\/p>\n

\nStoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine. Using Stoke\u2019s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore naturally-occurring protein levels. Stoke\u2019s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is currently being evaluated in a Phase 3 study. Stoke\u2019s initial focus are diseases of the central nervous system and the eye that are caused by a loss of ~50% of normal protein levels (haploinsufficiency). Proof of concept has been demonstrated in other organs, tissues, and systems, supporting broad potential for Stoke\u2019s proprietary approach. Stoke is headquartered in Bedford, Massachusetts. For more information, visit https:\/\/www.stoketherapeutics.com\/<\/a>.<\/p>\n

About Zorevunersen<\/b><\/p>\n

\nZorevunersen is an investigational antisense oligonucleotide that is designed to treat the underlying cause of Dravet syndrome by increasing functional NaV1.1 protein production in brain cells from the unaffected (wild-type) copy of the SCN1A<\/i> gene. This highly differentiated mechanism of action aims to reduce seizure frequency beyond what has been achieved with anti-seizure medicines and to improve neurodevelopment, cognition and behavior. Zorevunersen has demonstrated the potential for disease modification and has been granted orphan drug designation by the FDA and the EMA. The FDA has also granted zorevunersen rare pediatric disease designation and Breakthrough Therapy Designation for the treatment of Dravet syndrome with a confirmed mutation not associated with gain-of-function, in the SCN1A<\/i> gene. Stoke has a strategic collaboration with Biogen (Nasdaq: BIIB) to develop and commercialize zorevunersen for Dravet syndrome. Under the collaboration, Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260408281696\/en\/<\/a><\/span><\/p>\n

Stoke Media & Investor Contacts:
\n<\/b>
Susan Willson
\n
Vice President, Corporate Communications
\n
swillson@stoketherapeutics.com
\n<\/a>
415-509-8202<\/p>\n

\nDoug Snow
\n
Director, Communications & Investor Relations
\n
IR@stoketherapeutics.com
\n<\/a>
508-642-6485<\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Genetics Other Science Clinical Trials Science Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:00 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke\u2019s website at https:\/\/investor.stoketherapeutics.com\/. About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company … <\/p>\n

Continue reading “Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-949939","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nStoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:00 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke\u2019s website at https:\/\/investor.stoketherapeutics.com\/. About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company … Continue reading "Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T20:04:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference\",\"datePublished\":\"2026-04-08T20:04:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\"},\"wordCount\":483,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\",\"name\":\"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-04-08T20:04:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk","og_description":"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body\u2019s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:00 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke\u2019s website at https:\/\/investor.stoketherapeutics.com\/. About Stoke Therapeutics Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company … Continue reading \"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-08T20:04:24+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference","datePublished":"2026-04-08T20:04:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/"},"wordCount":483,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/","name":"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-04-08T20:04:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260408281696r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stoke-therapeutics-to-present-at-the-25th-annual-needham-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=949939"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/949939\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=949939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=949939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=949939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}